The Inflation Reduction Act’s broken promise is still costing patients - The Hill
Why now
Thesis: IRA drug-pricing criticism creates policy uncertainty for pharma margins.
Catalyst to watch: Legislative or regulatory changes to drug pricing.
Main risk: Pharma margins face continued pressure from uncertainty.
Why it matters
Criticism of IRA drug pricing could revive policy risk for pharma margins and pricing power.
Sources
- googlenews · news.google.com · 2026-09-16 17:00 UTC